February 26, 2010, Tokyo, Japan and Gurgaon, India

Daiichi Sankyo Company Limited (“Daiichi Sankyo”) and Ranbaxy Laboratories Limited (“Ranbaxy”) today announced that Daiichi Sankyo will establish Daiichi Sankyo Espha Co., Ltd. (“Daiichi Sankyo Espha”) on April 1st, 2010. Daiichi Sankyo Espha will market generic drugs, as well as Daiichi Sankyo’s products which have gained a well-established reputation in the market.

“Daiichi Sankyo is dedicated to meeting the universal desire of patients to improve their health and better balance their lives,” said Takashi Shoda, President & CEO of Daiichi Sankyo. “We believe that our understanding of the Japanese market and local presence united with the global expertise of Ranbaxy in the generic arena will enable us to achieve efficient and immediate entryinto the generic market.”

Remarking on the development, Atul Sobti, CEO and Managing Director of Ranbaxy, said, “Daiichi Sankyo’s leadership in the Japanese pharmaceutical market will guide us to further expand our business in Japan. Ranbaxy is committed to bringing high quality, affordable medicines to doctors and patients across the world.”

Completing their strategic alliance in November 2008 to form the unique Hybrid Business Model, Daiichi Sankyo and Ranbaxy (collectively “the Group”) have been moving forward to fully leverage the Model. The expanded global reach enables leading market positions in both developed and emerging markets through the supply of innovative and established pharmaceuticals.

In addition to meeting unmet medical needs through the development and marketing of outstanding new drugs, the Group also operates an OTC business, and is accelerating its efforts to reinforce its Vaccine business. In order to further fulfill the various needs patients have, the Group is also committed to providing patients with reliable generic pharmaceuticals through a strong network of Japanese and overseas companies. Leveraging Ranbaxy’s strengths, Daiichi Sankyo Espha will expand its product pipeline and continuously realize stable supply.

As a member of the Group, Daiichi Sankyo Espha will continue to respond to the expectations of patients, firmly coordinating the Group’s strengths through coordination of the most important elements of pharmaceuticals: quality, information, and stable supply.

Profile of Daiichi Sankyo Espha

About Daiichi Sankyo Company, Limited

A global pharma innovator, Daiichi Sankyo Company, Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.

About Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.

For further information, please contact: